Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Roquefort Therapeutics Plc | ROQ | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.15 | 3.57% | 4.35 | 11:07:47 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.20 | 4.10 | 4.35 | 4.35 | 4.20 |
| Industry Sector |
|---|
| GENERAL FINANCIAL |
| Top Posts |
|---|
Posted at 01/6/2024 05:41 by purple11 regards ROQ i think you have a problem with the CLN Death Spiral financing.it just kills sentiment atb |
Posted at 23/5/2024 15:03 by z1co Roquefort Therapeutics leaps on news term sheet for licencing deal with PDC23-05-2024 Shares of UK immune-oncology company Roquefort Therapeutics (LSE: ROQ) rose almost 24% to 5.51 pence this morning, following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. PDC is a leading MEA pharmaceutical research and development organization which has conducted over 150 clinical trials. This is a strategic out-licencing deal in which Roquefort Therapeutics receives $10 million total initial consideration&hellip |
Posted at 23/5/2024 07:44 by citys2874 Excellent news out for IXI and ROQ today. Very nice licencing deal agree zico |
Posted at 07/4/2024 14:31 by stockhunters look at the massive delayed trades showing on roq 2.40pm exactly when the price crateredand look at the timestamps phil (now deleted posts) around 3pm selling started before he posted |
Posted at 04/8/2023 15:00 by apotheki Yup ROQ are indeed looking rather good these days |
Posted at 03/3/2023 08:45 by the chairman elect which leads one to believe that potentially ROQ could go on to double or even treble in value from here |
Posted at 03/3/2023 08:44 by the chairman elect The ROQ chart looks like a coiled spring.... |
Posted at 24/1/2023 08:00 by the chairman elect Roquefort Therapeutics plc / LSE:ROQMDK Oncology Antibodies Demonstrate In-Vivo Safety Development milestone achieved Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high growth, high value oncology market is pleased to announce the ROQ-A1 and ROQ-A2 Midkine ("MDK") antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in pre-clinical development programs carried out by leading cancer research groups. As stated in the Company's announcement of 9 January 2023, Roquefort Therapeutics has recently signed partnership agreements and commenced pre-clinical development programs with leading academic cancer research groups at the Olivia Newton-John Cancer Research Institute (La Trobe University), Lowry Cancer Research Centre (University of New South Wales), Hawkins Laboratory Biochemistry and Genetics (La Trobe University) and the School of Medical Sciences (University of Sydney). ROQ-A1 and ROQ-A2 are the latest patented humanised antibody medicines designed by Roquefort Therapeutics to target the novel MDK target prevalent in hard-to-treat cancers. In laboratory experiments, ROQ-A1 and ROQ-A2 bind highly specifically to the MDK receptors in cancer cells to kill cancers in vitro. The MDK antibody programs targeting metastatic breast cancer and metastatic lung cancer commenced in Q4 2022 at La Trobe University, Melbourne in the Olivia Newton-John Cancer Research Institute and Hawkins Laboratory respectively and have now successfully reached the first pre-clinical drug development milestone. Metastatic breast cancer and metastatic lung cancer were chosen because of high patient mortality rates (~70% at five years) and prevalence of resistant MDK subtypes which can reduce effectiveness of existing therapies. Therefore, Roquefort Therapeutics is pleased that both ROQ-A1 and ROQ-A2 have demonstrated a good safety profile in validated in vivo models. These milestones were completed on schedule and within budget. Both MDK antibody programs will now progress into in vivo pre-clinical efficacy studies to assess cancer killing ability in primary and metastatic breast cancer and lung cancer. The Company will update the market on the results of these efficacy studies as they progress. Ajan Reginald, Chief Executive Officer of Roquefort Therapeutics, said: "We have started 2023 with significant momentum successfully completing these initial pre-clinical development milestones on schedule and within budget. The ROQ-A1 and ROQ-A2 antibodies are valuable assets that fit the established Big Pharma paradigm of treating cancer with novel antibody therapeutics. Therefore, we are pleased that both programs have shown the good safety profile that is particularly attractive for innovative cancer medicines targeting novel targets such as Midkine. Both programs will now progress rapidly into in vivo pre-clinical efficacy testing. The siRNA, MK cell therapy and Midkine oligonucleotide programs are also progressing well and are expected to complete development milestones in Q1, which we will update the market on in due course." |
Posted at 16/9/2022 06:40 by the chairman elect RNSs out @ ROQ |
Posted at 08/2/2022 15:00 by the chairman elect ROQ starting to stir |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
